Immuneering Presents New Genetic Data At 2026 AACR Annual Meeting; Analysis Of Circulating Tumor DNA From Atebimetinib-Treated Patients Shows Acquired MAPK Pathway Alterations Are Rare, Supporting Observed Durable First-Line Activity

Benzinga Newsdesk www.benzinga.com Positive 90.4%

Neg 0% Neu 0% Pos 90.4%

Comments

No comments yet. Be the first!